- Home
- OBIO vs IKT Comparison
OBIO vs IKT Comparison
Compare OBIO & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBIO
- IKT
- Stock Information
- Founded
- OBIO 2017
- IKT 2008
- Country
- OBIO United States
- IKT United States
- Employees
- OBIO N/A
- IKT N/A
- Industry
- OBIO Medicinal Chemicals and Botanical Products
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- OBIO Health Care
- IKT Health Care
- Exchange
- OBIO Nasdaq
- IKT Nasdaq
- Market Cap
- OBIO 151.3M
- IKT 167.2M
- IPO Year
- OBIO N/A
- IKT 2020
- Fundamental
- Price
- OBIO $4.28
- IKT $2.19
- Analyst Decision
- OBIO Strong Buy
- IKT Buy
- Analyst Count
- OBIO 5
- IKT 2
- Target Price
- OBIO $15.40
- IKT $8.00
- AVG Volume (30 Days)
- OBIO 51.3K
- IKT 124.8K
- Earning Date
- OBIO 05-12-2025
- IKT 05-14-2025
- Dividend Yield
- OBIO N/A
- IKT N/A
- EPS Growth
- OBIO N/A
- IKT N/A
- EPS
- OBIO N/A
- IKT N/A
- Revenue
- OBIO $2,647,000.00
- IKT N/A
- Revenue This Year
- OBIO $22.61
- IKT N/A
- Revenue Next Year
- OBIO $16.64
- IKT N/A
- P/E Ratio
- OBIO N/A
- IKT N/A
- Revenue Growth
- OBIO N/A
- IKT N/A
- 52 Week Low
- OBIO $3.75
- IKT $1.12
- 52 Week High
- OBIO $8.87
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- OBIO 45.19
- IKT 42.25
- Support Level
- OBIO $4.14
- IKT $2.08
- Resistance Level
- OBIO $4.67
- IKT $2.46
- Average True Range (ATR)
- OBIO 0.34
- IKT 0.15
- MACD
- OBIO 0.06
- IKT 0.01
- Stochastic Oscillator
- OBIO 51.70
- IKT 22.00
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.